| Followers | 2210 |
| Posts | 20761 |
| Boards Moderated | 0 |
| Alias Born | 04/13/2006 |
Sunday, April 08, 2012 3:31:13 PM
The moment when ATRN issued those 69 million shares is crucial, because ATRN had only about $5M in debt, so the stock was trading in the $2.5 price range, if the company diluted only 2.5M shares, they would pay all the debt, so this was really bad management, or a great plan to screw the shareholders.
Because whoever decided to delist the company, brought it to .008, and, gave 69M shares to pay all the debt, instead of just sell 2.5M shares at $2.50, committed a crime, I only don't know if it was by pure ignorance, or it was done intentionally to give the control to BD, but, this move needs to be explored.
I will still wait a few more days until the 10 work days pass, counting from the 15G.
This is just an opinion.
I advise to hold because I don't see the stock falling from here, I will hold all my shares.
P.S. - I can't reply to anyone, because I am restricted to only 1 post per day here.
Because whoever decided to delist the company, brought it to .008, and, gave 69M shares to pay all the debt, instead of just sell 2.5M shares at $2.50, committed a crime, I only don't know if it was by pure ignorance, or it was done intentionally to give the control to BD, but, this move needs to be explored.
I will still wait a few more days until the 10 work days pass, counting from the 15G.
This is just an opinion.
I advise to hold because I don't see the stock falling from here, I will hold all my shares.
P.S. - I can't reply to anyone, because I am restricted to only 1 post per day here.
Cheers
Dr Pennystock
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
- Nasdaq Top 5 Premarket Losers • IH Market News • 05/20/2025 12:47:37 PM
- Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm • IH Market News • 05/19/2025 02:28:09 PM
- Nasdaq Top 5 Premarket Gainers • IH Market News • 05/19/2025 01:07:08 PM
